Pharmaceuticals & Biotech Canadian Community

Catalysts Federal rescheduling of marijuana from Schedule I to Schedule III of the Controlled Substances Act is an inevitability from a scientific and sociopolitical perspective within five years. Rescheduling will eliminate the application of the punitive s.Read more

Cybin’s aggressive analyst price targets make sense when you view the company through a true late-stage biotech lens rather than a speculative psychedelic stock. With more than US$225 million in cash after retiring all debt, Cybin is now one of the only fully funded companies in the entire sector with enough runway to complete multiple Phase 3 trials and deliver two major clinical readouts—Phase 2 CYB004 data in Q1 2026 and pivotal Phase 3 CYB003 results in Q4 2026.Read more

BioNxt is developing two platform technologies: a sublingual thin-film technology (ODF) for smart drug delivery and a novel chemotherapy platform in which the active ingredient is activated directly in the tumor—targeting and killing cancer cells while sparing healthy cells. The ODF technology is protected by a European broad patent (intention-to-grant, May 2025), covering a wide range of sublingual active ingredients and is being nationalized in key markets.Read more

Organigram Holdings Inc. has seen some significant developments in the past four months: ✓ Acquisition of Motif Labs: In December 2024, Organigram acquired Motif Labs, a Canadian cannabis company, for C$90 million upfront.Read more

Cybin is pushing a psychedelic-based depression treatment that may work with only one or two sessions, which could make it easier to use than some existing options. Fast-track attention from U.S. regulators and upcoming trial results in depression and anxiety could be the next big make-or-break moments.Read more

Green Thumb aims to stand out in cannabis by pushing premium brands and ready-to-drink THC beverages that fit within today’s patchwork rules, while using its cash strength to buy up weaker rivals as the market consolidates. The big swing factor is whether looser rules and shifting consumer habits arrive soon enough to offset price pressure, higher compliance costs, and a softer shopper.Read more

Delivra Health Brands is trying to reach more shoppers by pushing into more retail stores across North America and stepping up its online sales and data tools. The upside rests on new products and deal-making gaining traction, but higher marketing spend and shifting customer habits could keep profits under pressure.Read more

DRI Healthcare Trust aims to profit from the rising demand for medicines by buying royalty income from drug makers, and a shift to running the business in-house could leave more cash to grow and return to investors. But higher borrowing costs, drug-pricing policy changes, and reliance on a few key medicines could make results bumpier than they look at first glance.Read more

HLS Therapeutics could see growing demand for its heart health medicines as Canada’s population ages and care shifts toward more digital patient support that helps people stay on treatment. But the story depends on a small handful of drugs and smooth approvals and coverage decisions, so setbacks could quickly hit sales and profits.Read more